Presentation on theme: "Patient Selection and Outcomes for Implantable Pain Therapies"— Presentation transcript:
1Patient Selection and Outcomes for Implantable Pain Therapies Faculty NameInstitutionCity State
2Learning Objectives Describe the treatment continuum model. Define pain types effectively treated with implantable pain therapies.Identify patient selection criteria for implantable pain therapies.Describe chronic pain indications, benefits and risks for neurostimulation and implantable drug delivery therapies.Describe the role of the psychological evaluation.Explain the importance of patient expectations.
3Definition of Chronic Pain Definitions include the following:1“It is not the duration of pain that distinguishes acute from chronic pain, but more importantly, the inability of the body to restore its physiological functions to normal homeostatic levels.”Chronic pain is commonly triggered by disease or injury.Stress, environmental, and affective factors may contribute to the pain experience.Chronic pain will continue when treatment stops.Chronic pain has only recently been explored as a complex condition that requires individual treatment and a multidisciplinary approach.When an adequate healing period has passed and the patient has not healed or reached homeostasis, the patient’s pain is considered chronic.1 Loeser JD and Melack R. Pain: an overview. The Lancet 1999; 53(9164):
4Device therapies are now considered earlier in the treatment continuum Pain Treatment Ladder1Device therapies are now considered earlier in the treatment continuumWhen an adequate healing period has passed and the patient has not healed or reached homeostasis, the patient’s pain is considered chronic.1 Stamatos JM, Forde G, Kechejian P et al. Live Your Life Pain Free: Medical Discoveries that Stop Chronic Pain. McKinney, TX: Magni Company; 2005.
5Implantable Pain Therapy Treatment Options NeurostimulationNeurostimulation—delivery of low-voltage electrical stimulation to the spinal cord to inhibit or mask the sensation of pain.Intrathecal Drug Delivery—blocks pain by delivering small doses of medication (e.g., morphine) directly into the spinal fluid.Intrathecal Drug Delivery
6How do pain types impact therapy selection? Pain types related to implantable pain therapies:Neuropathic painNociceptive painMixed painHow do pain types impact therapy selection?
7Neuropathic PainAssociated with injury to the peripheral nervous system or the spinal cordPerceived as shooting, shock-like pain with severe burning or aching sensationsMay have tingling, numbness, or itchingSevere cases have a ripping or tearing sensationMay be responsive to neurostimulation
8Nociceptive PainActivated in response to tissue damage or inflammation arising from receptors sensitive to noxious stimuliCan be perceived as:Well localized, constant, aching, throbbing, dull, vague, or a pressured feelingPoorly localized and diffuseSome patients describe as intermittent and sharp painOften responsive to opioid treatment; may be responsive to intrathecal drug delivery therapy
9Mixed Pain Most chronic pain is mixed pain. Mixed pain is a complex condition with neuropathic and nociceptive characteristics.Pain perception depends on the condition.Conditions likely to produce mixed pain include:Chronic low back pain.Some forms of cancer pain and treatment.Patient may respond to neurostimulation or intrathecal drug delivery therapy. Clinical judgment and patient characteristics guide therapy selection.
10Implantable Pain Therapy Selection Neurostimulation or Intrathecal Drug DeliveryIntrathecal Drug DeliveryNeurostimulationRadiculopathyPost laminectomy painEpidural fibrosisDegenerative disc diseasePeripheral causalgiaFailed back surgery syndrome• Complex regional pain syndrome• ArachnoiditisIntractable painChronic pain due to cancerThe etiology and pattern of the patient’s pain guide the selection of the appropriate implantable pain therapy.In general, neurostimulation is often indicated for neuropathic pain. Examples of neuropathic pain syndromes that typically respond well to neurostimulation include those listed above.Nociceptive pain, pain in multiple or axial sites, and even pain with a changing pattern may be better suited to intrathecal drug delivery. Pain syndromes that are typically most opioid-responsive include those listed above.
11Patient Selection Criteria for Implantable Pain Therapies: Non-malignant Pain Inadequate pain relief and/or intolerable side effects after treatment with more conservative therapiesPhysiological origin of the painNo current signs of drug abuse or addictionAppropriate surgical candidateAdditional surgical interventions are not indicatedPatient understands therapy limits and risksPatient can articulate goals of therapy and wants to participate in treatmentPsychological evaluation and clearance was obtainedA screening trial has been successfulPatient can properly operate the systemPatient is ≥ 18 years oldPatient is not pregnantAdditional surgical interventions may not be indicated due to the likelihood of complications or poor outcomes.
12Patient Selection Criteria for Implantable Pain Therapies: Malignant Pain Pain unrelieved by more appropriate conservative therapies1Life expectancy >3 months2No cerebrospinal fluid obstruction2Available network for post-surgical management2Trained healthcare providers and pharmacists, home health, or hospiceAbility to change dose or drugsAppropriate surgical candidate1 Follett K and Doleys D. Selection of Candidates for Intrathecal Drug Administration to Treat Chronic Pain: Considerations in Pre-implantation Trials. Minneapolis: Medtronic Inc., 2002:2 Smith T.J. and Coyne P.J. How to Use Implantable Drug Delivery Systems for Refractory Cancer Pain. J Supportive Oncology 1:1:1-4.
13NeurostimulationDelivery of low-voltage electrical stimulation to the spinal cord to inhibit or mask the sensation of pain.Treats chronic intractable neuropathic pain which results from injury to neural tissue that is involved in the transduction, modulation, transmission or perception of painNeurostimulation activates pain-inhibiting neuronal circuits in the dorsal horn and induces a tingling sensation (paresthesia) that masks the sensations of pain.
14History of Neurostimulation First implant of carotid sinus nerve stimulatorDevelopment of first “dorsal column” stimulator1970s - Spinal cord stimulator becomes widely usedMedtronic introduces first programmable electrode system in U.S.First clinical implant of Itrel® totally implantable neurostimulatorToday - More than 100,000 patients have received Medtronic neurostimulation therapy for chronic pain14
15Neurostimulation Indications Indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following conditions:Failed Back Syndrome or Low Back Syndrome or Failed BackRadicular Pain Syndrome or Radiculopathies resulting in pain secondary to Failed Back Syndrome or Herniated DiskPost-laminectomy PainMultiple Back OperationsUnsuccessful Disk SurgeryDegenerative Disk Disease (DDD)/Herniated Disk pain refractory to conservative and surgical interventionsPeripheral CausalgiaEpidural FibrosisArachnoiditis or Lumbar Adhesive ArachnoiditisComplex Regional Pain Syndrome (CRPS) or Reflex Sympathetic Dystrophy (RSD) or CausalgiaThe package labeling for neurostimulation products provides a complete list of indications, contraindications, warnings, precautions and adverse events.Refer to the package labeling for a completelist of indications.
16Potential Benefits of Neurostimulation for Chronic Pain1 May result in a 50% - 70% reduction in painMay reduce use of narcoticsMay increase ability to perform activities of daily livingIncreases ability to workMay be trialed to evaluate pain relief and functional improvement from therapyMay be reversedMay achieve long-term cost-effectiveness for batteries that last over one yearPain Relief (1st bullet): Neurostimulation provides ≥50% sustained pain relief in 62% of patients with persistent or recurrent FBSSCost effectiveness (last bullet): Conventional medical management is more cost effective when batteries last one year or less1 Taylor R, Caraway D, Van Buyten JP et al. eds. Spinal Cord Stimulation: Overcoming Barriers to Successful Outcomes for the Complex Pain Patient. Minneapolis: Medtronic Inc., 2006: 1-10.
17Risks of Neurostimulation for Chronic Pain1 The most frequently reported problems:InfectionLead movementPain at the implant siteLoss of therapy effectTherapy which did not meet the patient's expectationsSome of the most severe reported problems:Epidural hemorrhageSpinal fluid leakageParalysisFor a complete list of adverse events which have been associated with neurostimulation, please refer to the product labeling and information for prescribers.1 Medtronic Implantable Systems Performance Registry (ISPR) Annual Report. Protocol NSP Report date: October 2, 2008.
18Intrathecal Drug Delivery An implanted system to treat chronic pain; the system delivers precise doses of prescribed medication directly into the cerebrospinal fluid (CSF) to modulate the transmission of pain signalsTreats intractable pain – including cancer pain
19History of Intrathecal Drug Delivery First clinical implant of programmable pump (became SynchroMed pump) for intrathecal morphineMarket release of implantable programmable SynchroMed Pump (IV use for cancer chemotherapy)Market release of SynchroMed Pump (intrathecal morphine for cancer pain and non-malignant pain)Today - More than 100,000 patients worldwide have received a Medtronic pump for chronic pain19
20Intrathecal Drug Delivery Indications The SynchroMed® Pump is indicated for use when patient therapy requires the chronic intrathecal infusion of medications.Approved for use with:Preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain.Preservative-free ziconotide sterile solution for the management of severe chronic pain.Lioresal® Intrathecal (baclofen injection) in the management of severe spasticity.Chronic intravascular infusion of floxuridine (FUDR), methotrexate, doxorubicin or cisplatin for the treatment of primary or metastatic cancer.Refer to the package labeling for a complete list of indications.The package labeling for neurostimulation products provides a complete list of indications, contraindications, warnings, precautions and adverse events.Lioresal® is a registered trademark of Novartis Pharmaceuticals, Inc.
21Intrathecal Drug Delivery Contraindications IDD system implant is contraindicated when:Infection is present.When the pump cannot be implanted at the appropriate depth from the surface of the skin.Body size is insufficient to accommodate the pump.Contraindications exist relating to the drug (e.g., allergic reaction).Do not use the patient control device to administer opioid to opioid-naïve patients or to administer ziconotide or baclofen.Refer to the package labeling for a complete list of contraindications.
23Risks of Intrathecal Drug Delivery1,2 The most frequently reported problems:InfectionSpinal fluid leakPump inversionSkin erosionDrug side-effectsLoss of therapy effectTherapy which did not meet the patient's expectationsSome of the most severe reported problems:Inflammatory massSpinal cord damageMeningitisLife threatening drug adverse effects due to over infusion as a result of programming or patient monitoring errors or device malfunctionComplications due to use of unapproved drugs and/or not using drugs in accordance with drug labelingFor a complete list of adverse events which have been associated with intrathecal drug delivery, please refer to the product labeling and information for prescribers.1 Medtronic Implantable Systems Performance Registry (ISPR) Annual Report. Protocol NSP Report date: October 2, 2008.2 Coffey RJ, Owens, M, Broste, Steven K, et al. Mortality Associated with Intrathecal Opioid Drug Infusion to Treat Non-Cancer Pain: Risk Factors and Mitigation. Late breaking paper presented at: North American Neuromodulation Society 12th Annual Meeting; December 4-7; 2008; Las Vegas, NV.
24Patient EvaluationObtain patient history and conduct physical examinationAssess and document patient’s pain-related symptomsEvaluate other appropriate and less invasive therapiesAssess patient motivation and commitment to the therapyEstablish reasonable goals for the therapy:Reduce painReduce use of oral medication and side effectsImprove functionImprove quality of life
25Psychological Evaluation A psychological evaluation can be used to identify patients with characteristics that are positive indicators to a successful outcome.1Assess existence of significant psychological signs, drug addiction or behavioral problems and unresolved issues of secondary gain.Identify and treat psychological co-morbidities prior to therapy.Evaluate patient willingness, understanding, and competency to actively participate in their therapy.Establish a baseline against which to measure improvement.1Doleys DM. .Psychological factors in spinal cord stimulation therapy: brief review and discussion. Neurosurgical Focus 2006: 21(6):1-6.
26Patient Expectations Candidates must: Be able to determine specific, measurable goals, and expectations for the therapy.Want pain to decrease and ability to function to improve.Understand that pain has multiple components.Express realistic expectations about treatment outcomes.Be able and willing to participate in therapy and rehabilitation.
27ReferencesCoffey RJ, Owens, M, Broste, Steven K, et al. Mortality Associated with Intrathecal Opioid Drug Infusion to Treat Non-Cancer Pain: Risk Factors and Mitigation. Late breaking paper presented at: North American Neuromodulation Society 12th Annual Meeting; December 4-7; 2008; Las Vegas, NV.de Lissovoy G, Brown RE, Halpern M et al. Cost Effectiveness of Long-term Intrathecal Morphine for Pain Associated with Failed Back Surgery Syndrome. Clinical Therapeutics 1997;19(1):96–112.Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for low back pain. Pain Med 2004;5(1):6-13.Doleys DM.Psychological factors in spinal cord stimulation therapy: brief review and discussion. Neurosurgical Focus 2006: 21(6):1-6.Doleys DM and Olson K ed. Psychological assessment and intervention in implantable pain therapies. Minneapolis: Medtronic Inc., 1996: 1-20.Follett K and Doleys D. Selection of Candidates for Intrathecal Drug Administration to Treat Chronic Pain: Considerations in Pre-implantation Trials. Minneapolis: Medtronic Inc., 2002:
28References continuedKumar K, Hunter G, Demaria D. Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience. Neurosurgery. 2006;58(3):Loeser JD and Melack R. Pain: an overview. The Lancet 1999;353(9164):North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56(1):Medtronic Implantable Systems Performance Registry (ISPR) Annual Report. Protocol NSP Report date: October 2, 2008.Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5(4):Smith T.J. and Coyne P.J. How to Use Implantable Drug Delivery Systems for Refractory Cancer Pain. J Supportive Oncology 1:1:1-4.Taylor R, Caraway D, Van Buyten JP et al. eds. Spinal Cord Stimulation: Overcoming Barriers to Successful Outcomes for the Complex Pain Patient. Minneapolis: Medtronic Inc., 2006: 1-10.Van Buyten JP, Van Zundert J, Vueghs P, Vanduffel L. Efficacy of spinal cord stimulation: 10 years of experience in a pain centre in Belgium. Eur J Pain. 2001;5(3):
29Neurostimulation Systems for Pain Therapy Brief Summary (continued) ContraindicationsDiathermy - Do not use shortwave diathermy, microwave or therapeutic ultrasound diathermy (all now referred to as diathermy) on patients implanted with a neurostimulation system. Energy from diathermy can be transferred through the implanted system and cause tissue damage at the locations of the implanted electrodes, resulting in severe injury or death.WarningsSources of strong electromagnetic interference (eg, defibrillation, diathermy, electrocautery, MRI, RF ablation, and therapeutic ultrasound) can interact with the neurostimulation system, resulting in serious patient injury or death. These and other sources of EMI can also result in system damage, operational changes to the neurostimulator or unexpected changes in stimulation. Rupture or piercing of the neurostimulator can result in severe burns. An implanted cardiac device (eg, pacemaker, defibrillator) may damage a neurostimulator, and the electrical pulses from the neurostimulator may result in an inappropriate response of the cardiac device.PrecautionsThe safety and effectiveness of this therapy has not been established for pediatric use (patients under the age of 18), pregnancy, unborn fetus, or delivery. Patients should be detoxified from narcotics prior to lead placement. Clinicians and patients should follow programming guidelines and precautions provided in product manuals. Patients should avoid activities that may put undue stress on the implanted neurostimulation system components. Patients should not scuba dive below 10 meters of water or enter hyperbaric chambers above 2.0 atmosphere absolute (ATA). Electromagnetic interference, postural changes, and other activities may cause shocking or jolting.
30Neurostimulation Systems for Pain Therapy Brief Summary Product manuals must be reviewed prior to use for detailed disclosure.IndicationsImplantable neurostimulation systems - A Medtronic implantable neurostimulation system is indicated for spinal cord stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain associated with the following conditions:Failed Back Syndrome (FBS) or low back syndrome or failed backRadicular pain syndrome or radiculopathies resulting in pain secondary to FBS or herniated diskPostlaminectomy painMultiple back operationsUnsuccessful disk surgeryDegenerative Disk Disease (DDD)/herniated disk pain refractory to conservative and surgical interventionsPeripheral causalgiaEpidural fibrosisArachnoiditis or lumbar adhesive arachnoiditisComplex Regional Pain Syndrome (CRPS), Reflex Sympathetic Dystrophy (RSD), or causalgia
31Neurostimulation Systems for Pain Therapy Brief Summary (continued) Adverse EventsAdverse events may include: undesirable change in stimulation described by some patients as uncomfortable, jolting or shocking; hematoma, epidural hemorrhage, paralysis, seroma, CSF leakage, infection, erosion, allergic response, hardware malfunction or migration, pain at implant site, loss of pain relief, chest wall stimulation, and surgical risks.For further information, please call Medtronic at and/or consult Medtronic’s website atUSA Rx Only Rev 0209
32SynchroMed® II Drug Infusion System Brief Summary: Product technical manuals and the appropriate drug labeling must be reviewed prior to use for detailed disclosure.Indications:US: Chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, and chronic intrathecal infusion of Lioresal® Intrathecal (baclofen injection) for the management of severe spasticity; chronic intravascular infusion of floxuridine (FUDR) or methotrexate for the treatment of primary or metastatic cancer. Outside of US: Chronic infusion of drugs or fluids tested as compatible and listed in the product labeling.Contraindications:Infection; implant depth greater than 2.5 cm below skin; insufficient body size; spinal anomalies; drugs with preservatives, drug contraindications, drug formulations with pH < 3, use of catheter access port (CAP) kit for refills or of refill kit for catheter access, blood sampling through CAP in vascular applications, use of Personal Therapy Manager to administer opioid to opioid-naïve patients or to administer ziconotide.
33SynchroMed® II Drug Infusion System Brief Summary:(continued) Warnings:Non-indicated formulations may contain neurotoxic preservatives, antimicrobials, or antioxidants, or may be incompatible with and damage the system. Failure to comply with all product instructions, including use of drugs or fluids not indicated for use with system, or of questionable sterility or quality, or use of non-Medtronic components or inappropriate kits, can result in improper use, technical errors, increased risks to patient, tissue damage, damage to the system requiring revision or replacement, and/or change in therapy, and may result in additional surgical procedures, a return of underlying symptoms, and/or a clinically significant or fatal drug under- or overdose. Refer to appropriate drug labeling for indications, contraindications, warnings, precautions, dosage and administration information, screening procedures and underdose and overdose symptoms and methods of management. Physicians must be familiar with the drug stability information in the product technical manuals and must understand the dose relationship to drug concentration and pump flow rate before prescribing pump infusion. Implantation and ongoing system management must be performed by individuals trained in the operation and handling of the infusion system. An inflammatory mass that can result in serious neurological impairment, including paralysis, may occur at the tip of the implanted catheter. Clinicians should monitor patients on intraspinal therapy carefully for any new neurological signs or symptoms, change in underlying symptoms, or need for rapid dose escalation.
34SynchroMed® II Drug Infusion System Brief Summary:(continued) Inform patients of the signs and symptoms of drug under- or overdose, appropriate drug warnings and precautions regarding drug interactions, potential side effects, and signs and symptoms that require medical attention, including prodromal signs and symptoms of inflammatory mass. Failure to recognize signs and symptoms and seek appropriate medical intervention can result in serious injury or death. Instruct patients to notify their healthcare professionals of the implanted pump before medical tests/procedures, to return for refills at prescribed times, to carry their Medtronic device identification card, to avoid manipulating the pump through the skin, to consult with their clinician if the pump alarms and before traveling or engaging in activities that can stress the infusion system or involve pressure or temperature changes. Strong sources of electromagnetic interference (EMI), such as short wave (RF) diathermy and MRI, can negatively interact with the pump and cause heating of the implanted pump, system damage, or changes in pump operation or flow rate, that can result in patient injury from tissue heating, additional surgical procedures, a return of underlying symptoms, and/or a clinically significant or fatal drug underdose or overdose. Avoid using shortwave (RF) diathermy within 30 cm of the pump or catheter. Effects of other types of diathermy (microwave, ultrasonic, etc.) on the pump are unknown. Drug infusion is suspended during MRI; for patients who can not safely tolerate suspension, use alternative drug delivery method during MRI. Patients receiving intrathecal baclofen therapy are at higher risk for adverse events, as baclofen withdrawal can lead to a life threatening condition if not treated promptly and effectively. Confirm pump status before and after MRI. Reference product labeling for information on sources of EMI, effects on patient and system, and steps to reduce risks from EMI.
35SynchroMed® II Drug Infusion System Brief Summary:(continued) Precautions:Monitor patients after device or catheter replacement for signs of underdose/overdose. Infuse preservative-free (intraspinal) saline or, for vascular applications, infuse heparinized solutions therapy at minimum flow rate if therapy is discontinued for an extended period of time to avoid system damage. EMI may interfere with programmer telemetry during pump programming sessions. EMI from the SynchroMed programmer may interfere with other active implanted devices (e.g., pacemaker, defibrillator, neurostimulator).Adverse Events:Include, but are not limited to, spinal/vascular procedure risks; infection; bleeding; tissue damage, damage to the system or loss of, or change in, therapy that may result in additional surgical procedures, a return of underlying symptoms, and/or a clinically significant or fatal drug underdose or overdose, due to end of device service life, failure of the catheter, pump or other system component, pump inversion, technical/programming errors, or improper use, including use of non-indicated formulations and/or not using drugs or system in accordance with labeling; pocket seroma, hematoma, erosion, infection; post-lumbar puncture (spinal headache); CSF leak and rare central nervous system pressure-related problems; hygroma; radiculitis; arachnoiditis; spinal cord bleeding/damage; meningitis; neurological impairment (including paralysis) due to inflammatory mass; potential serious adverse effects from catheter fragments in intrathecal space, including potential to compromise antibiotic effectiveness for CSF infection; anesthesia complications; body rejection phenomena; local and systemic drug toxicity and related side effects; potential serious adverse effects from catheter placement in intravascular applications.USA Rx Only Rev 10/09